Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Updates from CheckMate 040 in Asian HCC patients

Thomas Yau, MD, MBBS, MRCP, FRCP, of the University of Hong Kong, Hong Kong, China, discusses the efficacy and safety of nivolumab and ipilumumab in Asian patients with advanced hepatocellular carcinoma (HCC) as evaluated in the CheckMate 040 study (NCT01658878). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).